This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

NCT06756451 | Recruiting Phase 1 FDA Drug

• 1 other identifier: RJK-RT2831-101
• Study Type: interventional
• Target: 71
• Locations: 1 country
• Sites: 16

Brief Summary

This study is a first-in-human (FIH) study which is required to understand the safety, tolerability, pharmacokinetics and preliminary efficacy of RJK-RT2831 injection in patients with hematologic malignancies

Conditions

Hematologic Malignancies

Keywords

RT-RT2831; Malignancies

Outcome Measures

Primary Outcomes (4)

• phase Ia and phase Ib: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

  All AEs (except for CRS and TLS) will be graded according to NCI CTCAE V5.0, a common standard term for AE. CRS and TLS will be graded according to ASCTC Consensus (2019) and Cairo-Bishop grading system (Howard revised) respectively.

  The summary of all AEs was dominated by adverse events that occurred during treatment, including any AE that occurred from the first administration of the study drug until 28 ± 7 days after the last administration.

• phase Ia: Maximum Tolerated Dose (MTD)

  To assess the safety, tolerability, and maximum tolerated dose (MTD) of RJK-RT2831 in patients with hematologic malignancies.

  From the first administration of the study drug until 28 days after the first dose

• phase Ia: Recommended Doses for Expansion (RDEs)

  To determine the recommended doses for expansion (RDEs) in patients with hematologic malignancies.

  From the first administration of the study drug until 28 ±7 days after the last administration and prior to the initiation of a new anti-tumor therapy

• phase Ib: Recommended Phase II Dose (RP2D)

  To determine the recommended Phase II dose (RP2D) in patients with hematologic malignancies.

  From the first administration of the study drug until 28 ±7 days after the last administration and prior to the initiation of a new anti-tumor therapy

Secondary Outcomes (15)

• Cmax

  The first 6 cycles (28 days/cycle)

• Tmax

  The first 6 cycles (28 days/cycle)

• Area under the concentration-time curve (AUC)

  The first 6 cycles (28 days/cycle)

• Total Clearance (CL)

  The first 6 cycles (28 days/cycle)

• Volume of distribution (Vd)

  The first 6 cycles (28 days/cycle)

Study Arms (1)

RJK-RT2831

EXPERIMENTAL

Drug: RJK-RT2831 dose-escalation phase Ia; Drug: RJK-RT2831 Dose Expansion Phase Ib

Interventions

RJK-RT2831 dose-escalation phase Ia DRUG

there are seven doses(1mg-160mg) in this part. The subjects will receive RJK-RT2831 injection twice a week by intravenous push or intravenous infusion for 4 weeks until the end of one dosing cycle (28 days). After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).

RJK-RT2831

RJK-RT2831 Dose Expansion Phase Ib DRUG

there are four doses in this part. The subjects will be randomized in a 1:1 ratio to receive one dose level of RJK-RT2831 intravenous infusion twice a week for 4 weeks until the end of one dosing cycle (28 days).After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).

RJK-RT2831

Eligibility Criteria

• Age: 18 Years - 74 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. A male or female aged ≥ 18 and \<75 years old.
• \. The following three points are evaluated by the investigator and are deemed suitable to participate in the study: a) The subject fully understands the requirements of this study and voluntarily signs a written informed consent form; b) Be able to comply with the medication requirements of this study as well as all study related procedures and assessments; c) Not deemed as potentially unreliable and/or uncooperative.
• \. An ECOG physical status score is ≤ 2 and an expected survival is ≥ 3 months.
• \. Relapsed or refractory acute myeloid leukemia (AML) that meets the following criteria will be included in Phase Ⅰa : Patients diagnosed with AML according to the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours: -Myeloid and Histiocytic/Dendritic Neoplasms (Khoury et al., 2022), including any subtype except for acute promyelocytic leukemia (APL). These patients must have received at least one previous treatment and have failed to current standard treatments that provide clinical benefit.
• Note: The following diagnostic criteria must be met for relapsed/refractory AML: (1) Relapsed AML: Leukemia cells reappear in the peripheral blood or bone marrow blast cells exceed 5% after complete remission (CR) (excluding reasons such as bone marrow regeneration post-consolidation chemotherapy) or there is extramedullary infiltration by leukemia cells. (2) Refractory AML: Initial cases that are unresponsive after two cycles of standard regimen treatment; recurrence within 12 months after CR and consolidation therapy; recurrence beyond 12 months with ineffectiveness of conventional chemotherapy; those who have relapsed twice or more; or persistent extramedullary leukemia.;
• Phase Ib tentatively includes patients with hematologic malignancies that meet the following criteria: relapsed or refractory AML subjects who have received at least one previous treatment and have failed to current standard treatments that provide clinical benefit, and MDS subjects who are diagnosed according to the 5th edition of the WHO Classification of Haematolymphoid Tumours-Myeloid and Histiocytic/Dendritic Neoplasms (Khoury et al., 2022) and are classified as high-risk or very-high-risk according to the Revised International Prognostic Scoring System (IPSS-R) (Greenberg et al., 2012). The specific tumor type will be determined based on the results of the Phase Ia trial and may be extended to other hematologic malignancies.
• \. The test of CD33 and/or CD123 for Phase Ia and Ib subjects in this study will be required to be positive, and patients with any level of CD33 and/or CD123 positivity were allowed to be included. Note: The positivity and expression levels of CD33 and CD123 were determined by each site.
• \. Consent to bone marrow biopsy and aspiration, and consent to implantation of medical devices such as peripherally inserted central catheter (PICC), or venous access port, or central venous catheter (CVC) (if applicable) for long-term intravenous drug administration.
• \. Patients have recovered from toxicity of prior first-line therapy, i.e., Grade 1 toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0, with the exception of toxicities such as alopecia, fatigue, and other toxicities deemed by the investigator to be of no safety risk to the patient, as well as hematological toxicities related to the tumor.
• \. Substantial normal function of major organs with screening laboratory tests meeting the following criteria:
• Bone marrow function: white blood cell count ≤ 30×10\^9/L;
• Liver function: TBIL ≤ 1.5×ULN, TBIL ≤ 3×ULN if Gilbert's syndrome; ALT and AST ≤ 3 ×ULN;
• Renal function: creatinine clearance rate (CCr) \> 50 mL/min calculated according to the Cockcroft-Gault method
• Coagulation function: activated partial thromboplastin time (APTT) and prothrombin time (PT) ≤ 1.5×ULN.
• \. The serum pregnancy test for female patients of childbearing potential should be negative during the screening period. Male and female patients of childbearing potential must agree to use effective methods of contraception from signing an informed consent form during the screening period, throughout the study and for 3 months after the last dose of the RJK-RT2831, including but not limited to: abstinence, vasectomy in males, female sterilization surgery, effective intrauterine contraceptive devices or condoms, and effective contraceptive medications.. Note: Women of non-childbearing potential include permanent infertility (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) and postmenopausal women.

You may not qualify if:

• \. APL is suspected or confirmed based on morphology, immunophenotyping, molecular testing, or chromosomal karyotyping, or other hematological tumors, such as myeloid sarcoma, mixed phenotype acute leukemia, accelerated phase and blast phase of chronic myeloid leukemia, etc.;
• \. Has received any anticancer therapy or investigational drug within the following specified time period prior to the first dose of RJK-RT2831:
• Received cytotoxic chemotherapy (except hydroxyurea use for subjects with leukocytosis \>10,000 cells/mm3 or rapid disease progression), radiotherapy (except local palliative radiotherapy), immunotherapy, targeted therapy and other anti-tumor treatments within 14 days;
• Received adoptive cell therapy, such as autologous or donor natural killer cell or T lymphocyte infusions (e.g., chimeric antigen receptor-T cells), unless \> 60 days prior to the first dose of study treatment and treatment-related toxicities have resolved to at least Grade 1;
• Received any investigational drug (for any indication) within 5 half-lives of the drug or 14 days, whichever is longer;
• Received an autologous haematopoietic stem cell transplant within 12 weeks.
• \. Subjects with cardiovascular disease, including but not limited to:
• Resting state, mean QTcF \> 480 ms in men/women derived from 12-lead electrocardiogram (ECG) (repeated 3 times); Note: QTcF = QTcB ×RR\^0.17, QTcB is the corrected QT interval obtained using the Bazetts correction formula;
• Echocardiogram or multigated acquisition (MUGA) scan showing a left ventricular ejection fraction of less than 50%;
• Symptomatic or treatment-requiring abnormalities in rhythm, conduction, and resting ECG morphology, such as arrhythmias, degree II or III atrioventricular block, congestive heart failure (New York Heart Association cardiac function class III or IV)
• New onset of angina pectoris and myocardial infarction within 6 months prior to initiation of study treatment;
• Various factors that may increase the risk of prolonged QTc, such as congenital long QT syndrome, having long QT syndrome in the immediate family history, and being on any medications known to prolong the QT interval.
• History of cerebral perfusion (e.g., carotid artery stenosis) or stroke or transient ischemic attack within 6 months prior to screening.
• \. Subjects with an evidence of infectious disease, including:
• Hepatitis B surface antigen (HBs Ag) positive, and hepatitis B virus deoxyribonucleic acid (HBV DNA) copy number greater than the normal upper limit;

Sponsors & Collaborators

• Nanjing RegeneCore Biotech Co., Ltd.: lead

Study Sites (16)

The First Affiliated Hospital of USTC

Hefei, Anhui, 230001, China

RECRUITING

The Second Hospital of Anhui Medical University

Hefei, Anhui, 230601, China

RECRUITING

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China

RECRUITING

Southern Medical University Nanfang Hospital

Guangzhou, Guangdong, 510515, China

RECRUITING

Shenzhen People's Hospital

Shenzhen, Guangdong, 518020, China

RECRUITING

The Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, 541001, China

RECRUITING

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, 530021, China

RECRUITING

Affiliated Hospital of Hebei University

Baoding, Hebei, 071000, China

RECRUITING

Tangshan Central Hospital

Tangshan, Hebei, 063008, China

RECRUITING

Henan Cancer Hospital

Zhengzhou, Henan, 450003, China

RECRUITING

Zhongda Hospital Southeast University

Nanjing, Jiangsu, 210009, China

RECRUITING

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China

RECRUITING

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China

RECRUITING

The First Hospital of China Medical University

Shenyang, Liaoning, 110001, China

RECRUITING

The First Affiliated Hospital of Xi 'an Jiaotong University

Xi'an, Shaanxi, 710061, China

RECRUITING

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Tianjin, Tianjin Municipality, 300020, China

RECRUITING

MeSH Terms

Conditions

Hematologic Neoplasms; Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Hematologic Diseases; Hemic and Lymphatic Diseases

Central Study Contacts

Guo Qian

CONTACT

+86-025-58608860; guoqian@regenecore.com

Wang J xiang

CONTACT

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 27, 2024
• First Posted: January 3, 2025
• Study Start: March 25, 2025
• Primary Completion (Estimated): April 8, 2028
• Study Completion (Estimated): July 14, 2028
• Last Updated: January 30, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (16)